Literature DB >> 29423286

Acute visual loss in a patient with spinal cord injury.

Salman Farooq1, Kristin Garlanger2, John-Andrew Cox1, William Waring2.   

Abstract

INTRODUCTION: Patients with spinal cord injury (SCI), especially those with injury at and above T6, are prone to transient episodes of hypertension induced by noxious triggers below the level of SCI, known as autonomic dysreflexia (AD). An uncommonly reported presentation of AD is posterior reversible encephalopathy syndrome (PRES). CASE
PRESENTATION: A 50-year-old male with the history of paraplegia from SCI presented with sepsis secondary to baclofen pump and urinary tract infections. On hospital day 4, he developed acute bilateral vision loss. The next morning he had a generalized-tonic-clonic seizure followed by cardiac arrest, with return of spontaneous circulation following resuscitation. Magnetic resonance imaging brain demonstrated multifocal areas of hyperintensity on T2 fluid-attenuated inversion recovery sequence, most pronounced in the occipital lobes. Systolic blood pressures (SBP) were under 180 mmHg throughout hospital stay but above his baseline (SBP 90 mmHg). PRES was diagnosed on the basis of clinical and radiologic evidence. With strict blood pressure (BP) control, there was resolution of visual abnormalities, headaches, encephalopathy, and seizures. DISCUSSION: Although PRES has been most commonly described in malignant hypertension, it can be seen in patients with normotension or moderate hypertension who have low baseline BPs, such as patients with SCI. These patients are prone to AD due to imbalanced sympathetic outflow to vasculature below the level of injury caused by noxious stimulus. This results in massive regional vasoconstriction leading to an uncontrolled rise in BP above baseline. This episode of PRES could have been prevented by identifying patient's risk, recognizing early signs and potential triggers of AD, and implementing aggressive treatment of the underlying noxious stimuli.

Entities:  

Year:  2017        PMID: 29423286      PMCID: PMC5798915          DOI: 10.1038/s41394-017-0010-2

Source DB:  PubMed          Journal:  Spinal Cord Ser Cases        ISSN: 2058-6124


  8 in total

Review 1.  Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

2.  Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings.

Authors:  Jennifer E Fugate; Daniel O Claassen; Harry J Cloft; David F Kallmes; Osman S Kozak; Alejandro A Rabinstein
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

Review 3.  Autonomic dysreflexia: current evidence related to unstable arterial blood pressure control among athletes with spinal cord injury.

Authors:  Andrei Krassioukov
Journal:  Clin J Sport Med       Date:  2012-01       Impact factor: 3.638

4.  Cerebral hemorrhage due to posterior reversible encephalopathy syndrome associated with autonomic dysreflexia in a spinal cord injury patient.

Authors:  Tae Yamashita; Hisaya Hiramatsu; Naoto Sakai; Hiroki Namba
Journal:  Neurol Med Chir (Tokyo)       Date:  2012       Impact factor: 1.742

5.  Reversible posterior leukoencephalopathy in a patient with autonomic dysreflexia: a case report.

Authors:  C J Chaves; G Lee
Journal:  Spinal Cord       Date:  2008-04-22       Impact factor: 2.772

Review 6.  Neuroimaging in posterior reversible encephalopathy syndrome.

Authors:  C Lamy; C Oppenheim; J F Méder; J L Mas
Journal:  J Neuroimaging       Date:  2004-04       Impact factor: 2.486

Review 7.  Autonomic dysreflexia and posterior reversible encephalopathy syndrome.

Authors:  Ana Catarina Matias; João Rocha; Maria Emília Cerqueira; João Manuel Pereira
Journal:  Am J Phys Med Rehabil       Date:  2013-05       Impact factor: 2.159

Review 8.  Rehabilitation medicine: 1. Autonomic dysreflexia.

Authors:  Jeff Blackmer
Journal:  CMAJ       Date:  2003-10-28       Impact factor: 8.262

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.